Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 3 - Drugs for disorders of the metabolism
Patents for A61P 3 - Drugs for disorders of the metabolism (129,789)
09/2003
09/03/2003CN1440405A Sulfonyl-pyrrolidine derivatives useful for treatment of neurological disorders
09/03/2003CN1440401A Amino substituted dibenzothiophene derivatives for treatmnt of disorders mediated by NP Y5 receptor
09/03/2003CN1440396A Colchinol derivatives as angiogenesis inhibitors
09/03/2003CN1440395A COLCHINOL derivatives as vascular damaging agents
09/03/2003CN1440390A Substituted diamide derivatives useful as motilin antagonists
09/03/2003CN1440383A PPARγ调制剂 PPARγ modulators
09/03/2003CN1440294A Medical components comprising human parathyroid hormone and medicinal compositions for nasal administration containing the components
09/03/2003CN1440288A Heterocyclic compounds as inhibitors of enzyme DPP-IV
09/03/2003CN1440283A Combination of organic compounds
09/03/2003CN1440277A Particular carrier with active components with improved oral absorbing performance
09/03/2003CN1439628A Ferulaic acid esters and preparation and application thereof
09/03/2003CN1439429A Composite nutritive complementary tablets (particles)
09/03/2003CN1439383A Qifang sugar reducing instant preparation and its preparing method
09/03/2003CN1439361A Nutritive sustained release ball for ruminant
09/03/2003CN1439299A Intestinal absorbing fully nutrient emulsion for phymatostio patient
09/03/2003CN1439298A Cellulosefree intestinal absorbing nutrient emulsion and its preparing method
09/03/2003CN1439279A Luohan and cassia seed tea and its preparing method
09/03/2003CN1439274A Qifang sugar reduced nutrient flour and its production
09/03/2003CN1120015C High-efficient pure natural hypoglycemic agent
09/03/2003CN1120010C Scrophularia capsule and its preparing process
09/03/2003CN1119994C Oral preparation for prophylactic and therapeutic treatment of helicobacter sp. infection
09/02/2003US6613942 Glucagon antagonists/inverse agonists
09/02/2003US6613917 Amines substituted with a dihydronaphthalenyl, chromenyl, or thiochromenyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity
09/02/2003US6613916 Process for the preparation of amorphous atorvastatin
09/02/2003US6613913 Intermediate for antidepressant azaheterocyclylmethyl derivatives of 7,8-dihydro-1, 6,9-trioxa-3-aza-cyclopenta [a]naphthalene
09/02/2003US6613905 Chemokine receptor antagonists and methods of use therefor
09/02/2003US6613874 Melanocortin receptor ligands
09/02/2003US6613802 Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
09/02/2003US6613801 Method for the synthesis of compounds of formula I and their uses thereof
09/02/2003US6613796 Use of estrogen antagonists and estrogen agonists in inhibiting pathological conditions
09/02/2003US6613778 Imidazopyridine derivatives as phosphodiesterase VII inhibitors
09/02/2003US6613772 Substituted 2-aryl-4-amino-chinazolines, method for the production and use thereof as medicaments
09/02/2003US6613767 Stable aqueous folinate solution
09/02/2003US6613367 Complete nutrition of infants products are characterized by the type and amount of protein and carbohydrate and the increased levels of folic acid, vitamin B6 and vitamin B12 or their functional equivalents. These products improve feelings
08/2003
08/28/2003WO2003071273A1 Method of detecting bond between vitamin d3 derivative and vitamin d3 receptor
08/28/2003WO2003071268A2 Method for discovering pharmacologically active substances
08/28/2003WO2003070970A2 RNA INTERFERENCE MEDIATED INHIBITION OF NF-KAPPA B/REL-A GENE EXPRESSION USING SHORT INTERFEREING NUCLEIC ACID (siNA)
08/28/2003WO2003070969A2 RNA INTERFERENCE MEDIATED INHIBITION OF BCL2 GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
08/28/2003WO2003070968A2 RNA INTERFERENCE MEDIATED INHIBITION OF GASTRIC INHIBITORY POLYPEPTIDE (GIP) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
08/28/2003WO2003070918A2 Rna interference by modified short interfering nucleic acid
08/28/2003WO2003070914A2 RNA INTERFERENCE MEDIATED INHIBITION OF FOS GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
08/28/2003WO2003070911A2 Rna interference mediated inhibition of type 1 insulin-like growth factor receptor (igf-1r)
08/28/2003WO2003070903A2 RNA INTERFERENCE MEDIATED INHIBITION OF GRB2-ASSOCIATED BINDING PROTEIN 2 (GAB2) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
08/28/2003WO2003070886A2 Inhibition of protein tyrosine phosphatase type iva expression byshort interfering nucleic acid
08/28/2003WO2003070881A2 RNA INTERFERENCE MEDIATED INHIBITION OF PROTEIN TYPROSINE PHOSPHATASE-1B (PTP-1B) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
08/28/2003WO2003070765A2 Growth hormone fusion protein
08/28/2003WO2003070751A2 Partial peptide mimetics and methods
08/28/2003WO2003070747A2 Insulin and igf-1 receptor agonists and antagonists
08/28/2003WO2003070744A1 RNA INTERFERENCE MEDIATED INHIBITION OF INTERLEUKIN GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
08/28/2003WO2003070739A1 Partial and full agonists of a1 adenosine receptors
08/28/2003WO2003070738A2 Topiramate salts and compositions comprising and methods of making and using the same
08/28/2003WO2003070731A2 Azabicyclic compounds for the treatment of disease
08/28/2003WO2003070730A1 Pyrrolopyrimidine derivative
08/28/2003WO2003070729A1 Pyrrolopyrimidine derivatives
08/28/2003WO2003070727A1 Thiazolyl urea compounds for the treatment of cancer
08/28/2003WO2003070717A1 Process for the manufacture of hmg-coa reductase inhibitory mevalonic acid derivatives
08/28/2003WO2003070716A1 Vitamin d3 derivatives and remedies using the same
08/28/2003WO2003070709A1 Novel phenylalanine derivative
08/28/2003WO2003070707A1 Fused pyridazine derivative compounds and drugs containing the compounds as the active ingredient
08/28/2003WO2003070706A1 Tricyclic pyrazole derivatives for the treatment of inflammation
08/28/2003WO2003070702A1 Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation, as well as novel processes for preparing atorvastatin hemi-calcium forms i, viii and ix
08/28/2003WO2003070692A1 Novel propionic acid derivative
08/28/2003WO2003070276A1 A preparation and method for weight reduction
08/28/2003WO2003070275A1 Use of an inhibitor or antagonist against tissue factor
08/28/2003WO2003070263A1 Process for producing hydrophobic glycyrrhiza extract with high qualities
08/28/2003WO2003070261A1 Pharmacological substance from the plant tribulus terrestris
08/28/2003WO2003070244A1 Antagonist of melanin concentrating hormone and their uses
08/28/2003WO2003070220A1 Ph-sensitive cationic lipids, and liposomes and nanocapsules containing the same
08/28/2003WO2003070204A2 Lipase inhibiting composition
08/28/2003WO2003070197A2 RNA INTERFERENCE MEDIATED INHIBITION OF TGF-BETA AND TGF-BETA RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
08/28/2003WO2003070192A2 Compositions and methods for surrogate antibody modulation of an immune response and transport
08/28/2003WO2003070190A2 Surrogate antibodies and methods of preparation and use thereof
08/28/2003WO2003070188A2 Method of treating trx mediated diseases
08/28/2003WO2003070166A2 Novel tyloindicines and related processes, pharmaceutical compositions and methods
08/28/2003WO2003070023A1 Amino acid powder and process for producing the same
08/28/2003WO2003069997A1 Immunostimulant compositions comprising aminoalkyl glucosaminide phosphates and saponins
08/28/2003WO2003055911A3 Cystine-knot fold protein
08/28/2003WO2003037384A3 Polymer conjugates of protein kinase c inhibitors
08/28/2003WO2003028641A3 Mch receptor antagonists
08/28/2003WO2003027116A3 Substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1h)one derivatives
08/28/2003WO2003016335A3 Irreversible cysteine protease inhibitors of legumain
08/28/2003WO2003013434A3 Methods and compositions for treating diseases associated with excesses in ace
08/28/2003WO2003002559A3 Piperidine compounds for use as orexin receptor antagonist
08/28/2003WO2003002058A3 Bone anabolic compounds and methods of use
08/28/2003WO2002102359A3 Alkylidene pyrazolidinedione derivatives and use for treating diabetes and obesity
08/28/2003WO2002097044A3 Alternative splice forms of proteins as basis for multiple therapeutic modalities
08/28/2003WO2002096219A3 Acid controlled viscosity fiber system and uses thereof
08/28/2003WO2002094192A3 Antibodies against tumor necrosis factor delta (april)
08/28/2003WO2002081521A3 Osteoprotegerin in milk
08/28/2003WO2002079785A3 Phosphoprotein target for insulin and its antagonists
08/28/2003WO2002068687A3 Function and application of tob gene in central nervous system of mammal
08/28/2003WO2002034940A3 Methods for screening compounds that modulate lipid metabolism
08/28/2003WO2002008399A3 Human kinases
08/28/2003WO2001095859A3 Novel heterocyclic analogs of diphenylethylene compounds
08/28/2003WO2001085147A3 STABILIZED FORMULATIONS OF 6-HYDROXY-3-(4-[2-(PIPERIDIN-1-YL) ETHOXY]PHENOXY)-2-(4-METHOXYPHENYL) BENZO[b]THIOPHENE AND SALTS THEREOF
08/28/2003US20030163845 Elongase genes and uses thereof
08/28/2003US20030163834 Erk-5 deficient animals and methods of inhibiting angiogenesis through the inhibition of Erk-5
08/28/2003US20030162969 Process and intermediates for pyridazinone antidiabetic agents
08/28/2003US20030162968 1,4-Disubstituted benzo-fused urea compounds
08/28/2003US20030162964 Benzene-fused heterocycle derivatives and drugs containing the same as the active ingredient
1 ... 877 878 879 880 881 882 883 884 885 886 887 888 889 890 891 892 893 894 895 896 897 ... 1298